Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 29Stomach Neoplasms 13Esophageal Neoplasms 13Colorectal Neoplasms 12Esophageal Squamous Cell Carcinoma 10Rectal Neoplasms 7Pancreatic Neoplasms 7Biliary Tract Neoplasms 7Head and Neck Neoplasms 5Colonic Neoplasms 5Cholangiocarcinoma 5Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 4Locally Advanced Rectal Cancer 4Liver Neoplasms 4Ovarian Neoplasms 3Neoplasms 3Melanoma 3Carcinoma, Renal Cell 3Anus Neoplasms 3Turcot syndrome 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pathologic Complete Response 2Gastric / Gastroesophageal Junction Adenocarcinoma 2Digestive System Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1

Interventions

Oxaliplatin 3Fluorouracil 3Radiotherapy 2Immune Checkpoint Inhibitors 2Endoscopy 2Drug Therapy 2Chemoradiotherapy 2toripalimab 1tislelizumab 1pembrolizumab 1X-Rays 1Tretinoin 1TP protocol 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Proctectomy 1Positron Emission Tomography Computed Tomography 1Neoadjuvant Therapy 1Magnetic Resonance Imaging 1Leucovorin 1Immunotherapy 1Immunohistochemistry 1Esophagectomy 1Epirubicin 1Dynamic Contrast Enhanced Magnetic Resonance Imaging 1Docetaxel 1Diffusion Magnetic Resonance Imaging 1Cisplatin 1Capecitabine 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pathologic Complete Response × Immune Checkpoint Inhibitors × Gastrointestinal × Clear all
NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer(CONTROL-01)

The Affiliated Hospital of Qingdao University

Phase 2 Recruiting
35 enrolled
Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT06889402 2025-03-21

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting
600 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡